Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Are we done with dose-intense temozolomide in recurrent glioblastoma?

Literature DB >> 25063550

Are we done with dose-intense temozolomide in recurrent glioblastoma?

Martin J van den Bent¹, Walter Taal¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2014 PMID： 25063550 PMCID： PMC4136902 DOI： 10.1093/neuonc/nou157

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

23 in total

1. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.

Authors: W Wick; J P Steinbach; W M Küker; J Dichgans; M Bamberg; M Weller
Journal: Neurology Date: 2004-06-08 Impact factor: 9.910

2. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Authors: Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan
Journal: J Neurooncol Date: 2006-08-31 Impact factor: 4.130

3. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245

4. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Authors: H S Friedman; J Pluda; J A Quinn; R B Ewesuedo; L Long; A H Friedman; I Cokgor; O M Colvin; M M Haglund; D M Ashley; J N Rich; J Sampson; A E Pegg; R C Moschel; R E McLendon; J M Provenzale; E S Stewart; S Tourt-Uhlig; A M Garcia-Turner; J E Herndon; D D Bigner; M E Dolan
Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544

5. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245

6. MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245

7. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.

Authors: R B Mitchell; R C Moschel; M E Dolan
Journal: Cancer Res Date: 1992-03-01 Impact factor: 12.701

8. Phase I trial of temozolomide using an extended continuous oral schedule.

Authors: C S Brock; E S Newlands; S R Wedge; M Bower; H Evans; I Colquhoun; M Roddie; M Glaser; M H Brampton; G J Rustin
Journal: Cancer Res Date: 1998-10-01 Impact factor: 12.701

9. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Authors: A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky
Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640

10. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

Authors: A A Brandes; A Tosoni; G Cavallo; R Bertorelle; V Gioia; E Franceschi; M Biscuola; V Blatt; L Crinò; M Ermani
Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640

8 in total

Are we done with dose-intense temozolomide in recurrent glioblastoma?

1. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.

2. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

3. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

4. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

5. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

6. MGMT gene silencing and benefit from temozolomide in glioblastoma.

7. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.

8. Phase I trial of temozolomide using an extended continuous oral schedule.

9. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

10. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

1. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.

Review 2. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.

Review 3. Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.

4. Retrospective study of nivolumab for patients with recurrent high grade gliomas.

5. Cannabinoids in glioblastoma multiforme-hype or hope?

6. Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma.

7. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.

8. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.